ASCO GI Highlights

Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC

March 2023, Vol 4, No 1 — April 4, 2023

The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

ICIs as Salvage Therapy for BTCs with KRAS Mutation

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Results are presented from a retrospective analysis of molecular profiles in patients with biliary tract cancers to assess the efficacy of immune checkpoint inhibitors according to KRAS mutation.

Nivolumab with or without Ipilimumab plus SBRT in Pretreated Advanced BTC

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Second-line treatment options for patients with advanced biliary tract cancer are limited. Results from a randomized phase 2 study aimed at evaluating nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic disease are presented.

Current Epidemiological Data Can Help Predict Future Incidence of CCA

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

A recent epidemiological study showed that the incidence of cholangiocarcinoma has been increasing in the United States, and researchers sifted the data with an aim to help plan prevention and treatment strategies.

Survival Outcomes in Patients with iCCA and Solitary versus Multiple Tumors

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Researchers investigated risk factors for intrahepatic cholangiocarcinoma and the prognostic significance of tumor multiplicity identified by surgical resection.

Genetic Classification of iCCA Can Have Significant Prognostic Value

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

A retrospective review was conducted using the hidden-genome classifier to quantify the genetic heterogeneity of intrahepatic cholangiocarcinoma with a view toward improved tumor classification.

Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced CCA

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The clinical benefit of durvalumab plus GemCis in patients with advanced cholangiocarcinoma has been proved, but affordability of the regimen remains a concern. A cost analysis of this treatment regimen considers issues related to outcomes versus the financial toxicity experienced by patients.

CCA Summit Live from ASCO GI 2023

By Stacey Stein, MD

ASCO GI Highlights

Videos — January 26, 2023

On January 20, 2023, I presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2023). In addition, I provided my perspective on the impact of the data on the management of patients with CCA.

Erdafitinib in Asian Patients with Advanced CCA and FGFR Alterations: Updated Analysis

ASCO GI Highlights

March 2022, Vol 3, No 1 — March 29, 2022

The ongoing open-label, multicenter, phase 2a LUC2001 study is investigating the efficacy and safety of the FGFR inhibitor erdafitinib in a molecularly defined subset of Asian patients with advanced cholangiocarcinoma (CCA) harboring FGFR alterations whose disease progressed after ≥1 previous systemic therapies.

Sitravatinib plus Tislelizumab for Advanced Biliary Tract Cancer in Patients Whose Disease Did Not Respond to at Least 1 Systemic Therapy

ASCO GI Highlights

March 2022, Vol 3, No 1 — March 29, 2022

Given that monotherapy with immune checkpoint inhibitors, including the PD-1 inhibitor tislelizumab, has a modest effect in advanced biliary tract cancers, several combination strategies to improve the antitumor activity of immune checkpoint inhibitors are being explored.

ASCO GI Highlights

Subscribe Today!

I'd like to receive:

Stay In The Know

ASCO GI Highlights

Page 3 of 5

Subscribe Today!

I'd like to receive:

Stay In The Know